Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, was associated with increased mortality, and reduced by vutrisiran. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
Authors
- Emre Aldinc (ORCID: https://orcid.org/0000-0002-7237-4760)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Shaun Bender (ORCID: https://orcid.org/0000-0002-7589-4534)
- Patrick Y. Jay (ORCID: https://orcid.org/0000-0001-9429-5492)
- Satish A. Eraly
- Scott D Solomon
Institutions
- Brigham and Women's Hospital (US)
- Alnylam Pharmaceuticals (United States) (US)
- Columbia University Irving Medical Center (US)
- The Royal Free Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-11-18
- DOI
- https://doi.org/10.1016/j.jacc.2024.11.015
- Citations
- 20
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.68
Funders
- Alnylam Pharmaceuticals